1. Patients with systemic lupus erythematosus (SLE) have a unique miRNA signature in bone marrow-derived mesenchymal stem cells (BMSCs).
2. MiR-663 is closely associated with SLE disease activity and inhibits the proliferation and migration of BMSCs.
3. MiR-663 overexpression weakens the therapeutic effect of BMSCs, while miR-663 inhibition improves the remission of lupus disease in MRL/lpr mice.
The article “MicroRNA-663 induces immune dysregulation by inhibiting TGF-β1 production in bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus | Cellular & Molecular Immunology” is a well written and comprehensive article that provides an overview of the role of microRNAs in autoimmune diseases, specifically focusing on their role in mesenchymal stem cell dysfunction in systemic lupus erythematosus (SLE). The authors provide evidence to support their claims, including data from clinical studies and animal models, as well as references to other relevant research. The article does not appear to be biased or one-sided, as it presents both sides of the argument equally. It also does not appear to contain any promotional content or partiality towards any particular viewpoint. Furthermore, potential risks are noted throughout the article, such as the potential for miR-663 inhibition to worsen SLE symptoms if used incorrectly. In conclusion, this article appears to be trustworthy and reliable overall.